2098280-42-1
2098280-42-1
Chemical Structure
Zampilimab
Synonym(s): UCB-7858
- No. CAS: 2098280-42-1
- Formula:N/A
- Molecular Weight:(143.48 kDa)
SMILES: [Zampilimab]
Biological Activity: Zampilimab (UCB-7858) is a monoclonal antibody against transglutaminase 2 (TG2). Zampilimab inhibits TG2 crosslinking transamidation activity with an IC50 of 0.25 nM and a Kd of <50 pM. Zampilimab improves renal fibrosis[1][2][3].
| Referencia número | Nombre del producto | Pureza | Descripciòn | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Zampilimab | ≥99.0% | Zampilimab (UCB-7858) is a monoclonal antibody against transglutaminase 2 (TG2). Zampilimab inhibits TG2 crosslinking transamidation activity with an IC50 of 0.25 nM and a Kd of <50 pM. Zampilimab improves renal fibrosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Tempest R, et al. The Biological and Biomechanical Role of Transglutaminase-2 in the Tumour Microenvironment. Cancers (Basel). 2021 Jun 3;13(11):2788. [Content Brief]
- [2]. Prat-Duran J, et al. Transglutaminase 2 as a novel target in chronic kidney disease - Methods, mechanisms and pharmacological inhibition. Pharmacol Ther. 2021 Jun;222:107787. [Content Brief]
- [3]. Huang L, et al. The effect of TG2-inhibitory monoclonal antibody zampilimab on tissue fibrosis in human in vitro and primate in vivo models of chronic kidney disease. PLoS One. 2024 May 16;19(5):e0298864. [Content Brief]
